How to optimize HCV therapy in genotype 1 patients: Predictors of response

Liver International

Volumn 33, Issue SUPPL. 1, 2013, Pages 23-29

  Petta, Salvatore ^a   Craxì, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Chronic hepatits C; Triple therapy

Indexed keywords

BOCEPREVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ANTIVIRAL THERAPY; DRUG EFFICACY; DRUG TOLERABILITY; DUAL THERAPY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; NONHUMAN; POSTMARKETING SURVEILLANCE; PROCESS OPTIMIZATION; RAPID VIROLOGICAL RESPONSE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; TRIPLE THERAPY;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INDIVIDUALIZED MEDICINE; INTERLEUKINS; LIVER CIRRHOSIS; PATIENT SELECTION; PHARMACOGENETICS; RISK FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84872024767     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12053     Document Type: Review

References (27)

1. Welsch C, Jesudian A, Zeuzem S, Jacobson I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 2012; 61(Suppl. 1): i36-46.
2. Poordad F, McCone J Jr, Bacon BR, et al., SPRINT-2 Investigators Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
3. Jacobson IM, McHutchison JG, Dusheiko G, et al., ADVANCE Study Team Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
4. Sherman KE, Flamm SL, Afdhal NH, et al., ILLUMINATE Study Team Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
5. Bacon BR, Gordon SC, Lawitz E, et al., HCV RESPOND-2 Investigators Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
6. Bronowicki JP, Davis M, Flamm S, et al. Sustained virological response (SVR) in prior peginterferon/ribavirin (PR) treatment failure after retreatment with boceprevir (BOC)-+-PR: the PROVIDE study interim results. J Hepatol 2012; 56(Suppl. 2): S611.
7. Zeuzem S, Andreone P, Pol S, et al., REALIZE Study Team Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
8. Cammà C, Petta S, Enea M, et al., on behalf of the WEF Study Group. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012; 56: 850-60.
9. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-9. e18.
10. Moreno C, Deltenre P, Pawlotsky JM, et al. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. J Hepatol 2010; 52: 25-31.
11. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
12. Ghany M, Nelson D, Strader D, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis c virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.
13. Aronsohn A, Jensen D. Informed deferral: a moral requirement for entry into the HCV treatment warehouse. Hepatology 2012; 56: 1591-2.
14. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-16.
15. Victrelis [boceprevir]. European Medicines Agency. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002332/human_med_001464.jsp. Accessed: 17 August 2011.
16. Incivo [telaprevir]. European Medicines Agency. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_product_Information/human/002313/WC500115529.pdf
17. Incivek. Package insert. Cambridge, MA: Vertex Pharmaceuticals Inc, 2011.
18. Victrelis. Package insert. Whitehouse Station, NJ: Merck and Co, Inc, 2011.
19. Harrington PR, Zeng W, Naeger LK. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 2012; 55: 1048-57.
20. Parere dell'Associazione Italiana per lo Studio del Fegato (AISF) sull'uso della triplice-terapia (Peg-IFN + Ribavirina + inibitore delle proteasi di prima generazione) per il trattamento dei pazienti con epatite cronica da HCV genotipo 1. Available at http://www.webaisf.org/media/16360/position_paper_definitivo_26_01_12.pdf
21. Jacobson IM, Marcellin P, Zeuzem S, et al. Refinement of stopping rules during treatment of hepatitis c-genotype 1 infection with boceprevir combined with peginterferon/ribavirin. Hepatology 2012; 56: 567-75.
22. Poordad F, Bronowicki JP, Gordon SC, et al., SPRINT-2 and RESPOND-2 Investigators. Factors that predict response of patients with HCV infection to boceprevir. Gastroenterology 2012; 143: 608-18.e1-5.
23. Serfaty L, Forns X, Goeser T, et al. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut 2012; 61: 1473-80.
24. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011; 140: 459-68.
25. Muir AJ, Poordad FF, McHutchison JG, et al. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology 2011; 54: 1538-46.
26. Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol 2012; 57: 1110-25.
27. Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012; 32(S1): 88-102.